Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01847885
Other study ID # 0131-CSP-000
Secondary ID
Status Completed
Phase N/A
First received April 23, 2013
Last updated October 12, 2017
Start date April 2013
Est. completion date November 14, 2016

Study information

Verified date October 2017
Source SPR Therapeutics, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if electrical stimulation (small levels of electricity) reduces post-stroke shoulder pain. This study involves a device called the Smartpatch System. The Smartpatch System delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a "Lead") that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).


Recruitment information / eligibility

Status Completed
Enrollment 88
Est. completion date November 14, 2016
Est. primary completion date August 21, 2015
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Key Inclusion Criteria:

- At least 21 years of age

- Post-stroke shoulder pain

- At least 6 months after stroke that caused shoulder pain

Key Exclusion Criteria:

- Use of habit-forming (narcotic) medications

- Bleeding disorder

- History of recurrent skin infections

- Parkinson's Disease, Spinal Cord Injury, traumatic brain injury, Multiple Sclerosis, or Complex Regional Pain Syndrome

- Heart arrhythmia or artificial heart valves

- Uncontrolled seizures

- Implanted Electronic Device

- Pregnant

Study Design


Intervention

Device:
Smartpatch Peripheral Nerve Stimulation (PNS) System
The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a "Lead") that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator).

Locations

Country Name City State
United States Carolinas Rehabilitation/Carolinas Healthcare Charlotte North Carolina
United States Rehabilitation Institute of Chicago Chicago Illinois
United States The Ohio State University Wexner Medical Center Columbus Ohio
United States Weill Cornell Medical Center New York New York
United States Kessler Foundation Research Center West Orange New Jersey

Sponsors (1)

Lead Sponsor Collaborator
SPR Therapeutics, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other User Satisfaction With The Smartpatch System at End of Treatment Subjects completed the sponsor-developed Subject Satisfaction Survey at the End of Treatment (EOT) visit. The results of these surveys demonstrate the usability of the Smartpatch System and subject satisfaction with treatment. End of Treatment (4-weeks of Treatment/Control)
Other User Satisfaction With The Smartpatch System at 12-weeks Beyond Treatment Subjects completed the sponsor-developed Subject Satisfaction Survey at the end of the 12-week post-treatment period. The results of these surveys demonstrate the usability of the Smartpatch System and subject satisfaction with treatment. 12-week post-treatment
Other Performance of the Smartpatch System A sponsor-developed Clinician Satisfaction Survey was administered to the Investigator(s) at each site performing lead placement and included questions pertaining to use of the Smartpatch device as well as the overall impression of the therapy. At completion of study, approximately 2.5 years
Primary Change From Baseline Shoulder Pain Intensity at End of Treatment (EOT) A diary was used in the study to capture daily worst shoulder pain intensity over a 7-day period. The diary included a pain intensity question asked each day to the subject. The pain intensity question is excerpted from the Brief Pain Inventory - Short Form Question 3 (BPI-3) and is stated as "please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours". BPI-3 is a scale of 0 to 10 where 0 represents no pain and 10 represents worst pain. The median scores were calculated for each diary period. The median diary score at End of Treatment (EOT) was compared to the median baseline diary score to calculate the change in pain intensity. The group mean of the median scores for treatment was compared to the group mean of the medians scores for the control group at baseline and at EOT. Baseline, End of Treatment (4-weeks of Treatment/Control)
Primary Number of Participants With Device Related Adverse Event Rates in Treatment and Control Groups At each study visit following the baseline assessment, subjects were questioned if any changes in their medical status or condition had occurred. If the change was an adverse event, an adverse event form was completed by the site. 16 weeks total - 4 weeks from baseline visit to EOT visit, followed by 12 weeks post-treatment
Secondary Change From Baseline Shoulder Pain Interference at End of Treatment The degree to which shoulder pain interferes with daily activities was assessed using Question 9 of the Brief Pain Inventory (BPI-9) collected from the BPI Short Form administered during clinic visits. This question asks the subject to rate the degree to which their pain has interfered with general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life on a scale of 0 to 10, where 0 is "does not interfere" and 10 is "completely interferes" within the last week. The mean of these seven scores will be calculated to obtain the pain interference score. Baseline, End of Treatment (4-weeks of Treatment/Control)
Secondary Durability of Change From Baseline Shoulder Pain Intensity at 12-weeks Beyond Treatment A diary was used in the study to capture daily worst shoulder pain intensity over a 7-day period. The diary included a pain intensity question asked each day to the subject. The pain intensity question is excerpted from the Brief Pain Inventory - Short Form Question 3 (BPI-3) and is stated as "please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours". BPI-3 is a scale of 0 to 10 where 0 represents no pain and 10 represents worst pain. The median scores were calculated for each diary period. The median diary score at 12 weeks post-treatment was compared to the median baseline diary score to calculate the change in pain intensity. The group mean of the median scores for 12 weeks post-treatment was compared to the group mean of the median scores for the control group at baseline. Baseline, 12-wks post-treatment
Secondary Change From Baseline Quality of Life at End of Treatment The Medical Outcomes Study Short Form (SF-36v2) was administered at clinic visits to assess the impact of peripheral nerve stimulation on the subject's health-related quality of life. The SF-36v2 is a generic health survey designed to assess basic physical functioning and emotional well-being regardless of the disease or treatment. The 36 questions were grouped into two components: physical and mental. The survey was scored using norm-based scoring algorithm where a score of 0 indicates maximum disability and a score of 100 indicates no disability. Change in each component score was derived from End of Treatment score minus baseline score. Baseline, End of Treatment (4-weeks of Treatment/Control)
Secondary Change From Baseline Average Pain Intensity at End of Treatment A diary was used in the study to capture daily average shoulder pain intensity over a 7-day period. The diary included a pain intensity question asked each day to the subject. The pain intensity question is excerpted from the Brief Pain Inventory - Short Form Question 5 (BPI-5) and is stated as "please rate your pain by circling the one number that best describes your pain on the average". BPI-5 is a scale of 0 to 10 where 0 represents no pain and 10 represents worst pain. The mean scores were calculated for each diary period. The mean diary score at End of Treatment (EOT) was compared to the mean baseline diary score to calculate the change in pain intensity. Baseline, End of Treatment (4-weeks of Treatment/Control)
Secondary Patient Global Impression of Change at End of Treatment The Patient Global Impression of Change (PGIC) scale was administered at EOT to assess subject perception of overall improvement and patient preferences. The PGIC scale asks subjects to rate their improvement with treatment on a 7-point scale (centered at 4) that ranges from "very much worse" to "very much improved" relative to baseline. End of Treatment (4-weeks of Treatment/Control)
Secondary Change in Pain Medication Usage at End of Treatment Subjects completed 7-day diaries, in which they listed all pain medications they took during the 7 days. A blinded third party medication committee reviewed medications collected for each 7-day diary period and scored medication changes, in comparison to the baseline diary medications as "no change" (no change in dosage or change is not clinically meaningful to impact pain outcomes), "increase" (clinically meaningful increase in medication that would impact pain outcomes), or "decrease" (clinically meaningful decrease in medication that would impact pain outcomes). End of Treatment (4-weeks of Treatment/Control)
Secondary Clinical Global Impression of Improvement at End of Treatment The Blinded Evaluator rated each subject enrolled at their site using a question adapted from the Clinical Global Impression (CGI) scale, known as the Clinical Global Impression-Improvement scale (CGI-I). For the CGI-I, a Blinded Evaluator was asked to rate the subject's total improvement compared to their condition at baseline. The CGI-I uses a 7-point scale (centered at 4) that ranges from "very much worse" to "very much improved". End of Treatment (4-weeks of Treatment/Control)
See also
  Status Clinical Trial Phase
Recruiting NCT01572285 - Transforaminal Epidural Steroid Injection to Treat Hemiplegic Shoulder Pain N/A
Recruiting NCT05085236 - Fu's Subcutaneous Needling Treatment for Hemiplegic Shoulder Pain N/A
Recruiting NCT05395325 - Clinical Effects of Combined Kinesiotaping and Steroid Injection in Stroke Patients With Hemiplegic Shoulder Pain N/A
Completed NCT04292613 - "The Effect of Hemiplegic Shoulder Pain on Balance, Upper Extremity Function and Quality of Life"
Completed NCT04933318 - Effects of TENS and Interference on Pain, Functional Status and Range of Motion in Shoulder Pain in Stroke Patients N/A
Recruiting NCT06098508 - Osteopathic Manual Treatment for Hemiplegic Shoulder Pain and Upper Extremity Function in Stroke Patients N/A
Completed NCT06407596 - HILT or Conventional Combined Physical Therapy, in the Management of Hemiplegic Shoulder Pain N/A
Recruiting NCT04128605 - Suprascapular Nerve Block Versus Intraarticular Steroid Injection in Hemiplegic Shoulder Pain N/A
Terminated NCT03093935 - StimRouterâ„¢ for Pain Management in Post-stroke Shoulder Pain N/A
Recruiting NCT04758182 - Effects of High Intensity Laser Therapy Compared With Ultrasound Therapy on Hemiplegic Shoulder Pain; Randomized Control Trial N/A
Completed NCT06428851 - Laser Therapy Versus Neuromuscular Electrical Nerve Stimulation at Hemiplegic Shoulder Pain N/A
Completed NCT04768140 - Bobath Approach On Hemiplegic Shoulder Pain N/A